This article is more than 5 years old. Information may no longer be current.
Open angle glaucoma eye drop treatment in development
Click Here to Manage Email Alerts
Q BioMed Inc. announced that it has recently filed patents with the U.S. Patent and Trademark Office for its exclusively licensed platform technology asset from Mannin Research Inc.
Significant progress has been made on the Tie2 activating molecule (MAN-01 Program), which will be used in the treatment of open angle glaucoma, according to a press release from Q BioMed. The company said the recently filed patents cover “compounds capable of activating Tie2 receptor-mediated signaling” that can be delivered as an eye drop.
These new achievements required significant and detailed work from Q BioMed that will give them broader intellectual property coverage of the platform, according to the release. Additionally, the company is working on another project exploring a different treatment approach for glaucoma and other vascular diseases. The initial proof-of-concept data on biologic targeting Tie2 (MAN-11) will aid in the creation of a biologic-based therapeutic platform to target Tie2 receptors.
The MAN-01 Program will help to slow down or stop progression of vision loss and increase glaucoma treatment compliance with improved delivery profile of the drug, the company said.
Q BioMed said phase 1 clinical trials are planned for some time in 2019.